RT Journal Article
SR Electronic
T1 Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.05.19.104117
DO 10.1101/2020.05.19.104117
A1 Jinkai Wan
A1 Shenghui Xing
A1 Longfei Ding
A1 Yongheng Wang
A1 Dandan Zhu
A1 Bowen Rong
A1 Siqing Wang
A1 Kun Chen
A1 Chenxi He
A1 Songhua Yuan
A1 Chengli Qiu
A1 Chen Zhao
A1 Xiaoyan Zhang
A1 Xiangxi Wang
A1 Yanan Lu
A1 Jianqing Xu
A1 Fei Lan
YR 2020
UL http://biorxiv.org/content/early/2020/05/28/2020.05.19.104117.abstract
AB The coronavirus induced disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide threat to human lives, and neutralizing antibodies present a great therapeutic potential in curing affected patients. We purified more than one thousand memory B cells specific to SARS-CoV-2 S1 or RBD (receptor binding domain) antigens from 11 convalescent COVID-19 patients, and a total of 729 naturally paired heavy and light chain fragments were obtained by single B cell cloning technology. Among these, 178 recombinant monoclonal antibodies were tested positive for antigen binding, and the top 13 binders with Kd below 0.5 nM are all RBD binders. Importantly, all these 13 antibodies could block pseudoviral entry into HEK293T cells overexpressing ACE2, with the best ones showing IC50s around 2-3 nM. We further identified 8 neutralizing antibodies against authentic virus with IC50s within 10 nM. Among these, 414-1 blocked authentic viral entry at IC50 of 1.75 nM and in combination with 105-38 could achieve IC50 as low as 0.45 nM. Meanwhile, we also found that 3 antibodies could cross-react with the SARS-CoV spike protein. Altogether, our study provided a panel of potent human neutralizing antibodies for COVID19 as therapeutics candidates for further development.Competing Interest StatementFei Lan is a scientific advisor of Active Motif China Inc.